Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study

KE Kip, EK McCreary, K Collins, TE Minnier… - Annals of Internal …, 2023 - acpjournals.org
Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …
被引用次数：24 相关文章
[HTML] nih.gov

[HTML][HTML] Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19: A Cohort Study

KE Kip, EK McCreary, K Collins, TE Minnier… - Annals of Internal … - ncbi.nlm.nih.gov
Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study.

KE Kip, EK McCreary, K Collins, TE Minnier… - 2023 - cabidigitallibrary.org
Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19: A Cohort Study

KE Kip, EK McCreary, K Collins, TE Minnier… - 2023 - pubmed.ncbi.nlm.nih.gov
Background Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …